End stage renal failure on peritoneal dialysis or haemodialysis
documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation;
CHADS2-VASc \>=2
The patient is willing and able to comply with the required medication post-procedure and follow-up evaluations;
Able to consent
You may not be if
Patients who require long-term anticoagulation for a condition other than AF, e.g. pulmonary embolism, deep vein thrombosis, anti-phospholipid syndrome
Mechanical valve replacement
Active infection with bacteraemia;
Pregnant or nursing patients and those who plan pregnancy during the study period. Female patients of childbearing potential must have a negative pregnancy
Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, any device material or component (nickel titanium, PET, polypropylene), and/or contrast;
Left atrial appendage is obliterated and surgical ligated;
Underwent any cardiac or non-cardiac interventional or surgical procedure within 30 days prior to the procedure or planned to have the interventional or surgical procedure within 60 days after implant procedure (e.g., cardioversion, ablation, percutaneous coronary intervention, etc.);
Recent (within 90 days prior to procedure) stroke, transient ischemic attack, or myocardial infarction;
New York Heart Association Class IV;
Life expectancy is less than 1 year;
Current participation in another investigational drug or device study.
Echocardiogram exclusion:
i. Moderate mitral stenosis or above ii. LVEF \<30% iii. Intracardiac thrombus iv. Presence of a cardiac tumour. v. Existing circumferential pericardial effusion \>5 mm; vi. Presence of a high-risk Patent Foramen Ovale (PFO), defined as an atrial septal aneurysm (excursion \>15 mm or length \>15 mm) or large shunt (early, within 3 beats and/or substantial passage of 20 bubbles)
